SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Exelixis, Inc. (EXEL)
An SI Board Since January 2001
Posts SubjectMarks Bans Symbol
930 66 0 EXEL
Emcee:  kinkblot Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
255Exelixis Initiates Phase II Clinical Development Program for XL647 in Patients WLJM-8/1/2006
254Are folks here keeping an eye on Array's program in dual EGFR/HER2 inhibitiotuck-7/30/2006
253EXEL :Initiates Phase II Trial of XL880 2006-06-28 09:21 (New York) Piper Jaffrmopgcw-7/12/2006
252piper: EXEL :Spotlight On XL647 2006-06-05 05:41 (New York) (EXEL - $11.13) Outmopgcw-7/12/2006
251piper 6.06 xl880: * Over the weekend at ASCO, Exelixis presented a poster (Abstmopgcw-7/12/2006
250Exelixis Initiates Phase II Clinical Development Program for XL880 in Patients Wdr.praveen-6/28/2006
249<i>Interesting, and somewhat on topic...</i> Protein-protein interanigel bates-6/20/2006
248mstar: Exelixis EXEL presented data on its three most advanced experimental cancmopgcw-6/9/2006
247Thanks! Reread the PRs, and the multiple indications that were evaluated in thequidditch-6/3/2006
246quid: Two of two for the signal cancer, papillary renal cell. Numbers small, scaram(o)uche-6/3/2006
245Rick, at these early stage, based on these partial response/stable disease numbequidditch-6/3/2006
244Exelixis' XL880, the First Orally-Available MET Inhibitor in Clinical Develoscaram(o)uche-6/3/2006
243Press Release Source: Exelixis, Inc. Encouraging Phase I Trial Results for XL6scaram(o)uche-6/3/2006
242Exelixis Announces June 3 Webcast of Clinical Investigator Discussions of Phase keokalani'nui-5/25/2006
241New report on Exelixis: wrhambrecht.com From an EXEL fan:-)dr.praveen-5/10/2006
240From Yahoo In the very begining Drosophila (Fruit flies) were used in genetic sdr.praveen-4/29/2006
239Thanks Rick...I don't need to learn Genetics:-)dr.praveen-4/29/2006
238Not compounds, but fruit fly lines, from back in their worm and drosophila days.scaram(o)uche-4/28/2006
237flystocks.bio.indiana.edu Click on the left highlighted ones n you can see somedr.praveen-4/28/2006
236New report on Exelixis wrhambrecht.com PS:One of my core holdings Praveendr.praveen-4/24/2006
235gs: EXEL (IL/N): Alliance with Sankyo on third Nuclear Hormone Receptor platformmopgcw-4/21/2006
234I posted this on yahoo and wanted to see what you all thought... I've been biocat-4/9/2006
233niiiiiice, update, thanks!scaram(o)uche-4/4/2006
232I know that's optimistic for a phase 1. But if you look at it closely, he gadr.praveen-4/4/2006
231Thanks. Haven't read it yet, but a couple of early points: Probability of nigel bates-4/4/2006
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News